组织标本中组蛋白去乙酰化酶6蛋白水平与子宫内膜癌患者临床病理特征的关系

doi:10.3969/j.issn.1671-7171.2021.12.007

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1687 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the relationship between histone deacetylase 6 (HDAC6) protein level in tissue samples and clinicopathological features of patients with endometrial cancer. 【Methods】 A total of 90 patients with endometrial cancer who underwent surgery in our hospital from March 2018 to March 2020 was selected as the research objects. The specimens of cancer tissues and adjacent normal tissues of all patients after surgery were taken, and the expression of HDAC6 protein in tissue samples was measured by immunohistochemical staining. The positive rate of HDAC6 protein in cancer tissues and adjacent normal tissues of all patients and the expression of HDAC6 protein in cancer tissues of endometrial cancer patients with different clinicopathological features were compared. 【Results】The positive rate of HDAC6 protein in endometrial carcinoma was significantly higher than that in adjacent tissues (P<0.05). There was no significant difference in the positive rate of HDAC6 protein in endometrial cancer patients with different age, pathological classification, histological grade and cervical involvement (P>0.05); The positive rate of HDAC6 protein in patients with stage Ⅲ~Ⅳ was significantly higher than that in patients with stageⅠ~Ⅱ(P<0.05); The positive rate of HDAC6 protein in patients with lymph node metastasis was significantly higher than that in patients without lymph node metastasis (P<0.05); The positive rate of HDAC6 protein in patients with myometrial infiltration ≥ 1/2 was significantly higher than that in patients with myometrial infiltration < 1/2 (P<0.05). 【Conclusion】 The expression of HDAC6 protein is up-regulated in endometrial carcinoma, and its expression level is closely related to FIGO stage, lymph node metastasis and myometrial invasion depth.

Key words： Endometrial Neoplasms/PA Group Ⅲ Histone Deacetylases Neoplasm Staging Prognosis

Received: 31 August 2021

PACS:

R737.33

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2021.12.007 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2021/V38/I12/1780

[1] SHINSUKE S, MAYU Y, YAE T, et al. Baseline risk of recurrence in stage Ⅰ-Ⅱ endometrial carcinoma[J].J Gynecol Oncol,2018, 29(1):9.
[2] 周佳钦,曹佳璐,单静,等.MMR蛋白在子宫内膜癌组织中的表达水平及其临床意义[J].医学临床研究,2020,37(10):1532-1535.
[3] 詹佳琦, 马晓欣. miRNA-302d在子宫内膜癌组织中的表达及其与临床病理参数的关系[J].现代肿瘤医学,2018,26(9):1400-1403.
[4] 曹作增, 滕银成. 子宫内膜癌组织HER2表达水平与患者临床病理特征的关系探讨[J].癌症进展, 2017, 15(11):1312-1314.
[5] 邱教,彭栋柱,励辉辉,等. 组蛋白去乙酰化酶6抑制剂ACY1215对顺铂诱导肝癌细胞SMMC-7721凋亡的影响[J].中西医结合肝病杂志,2019,29(6):529-532.
[6] 连利娟. 林巧稚妇科肿瘤学[M]. 北京:人民卫生出版社, 2006:445-448.
[7] 林仲秋. FIGO/IGCS妇科恶性肿瘤分期及临床实践指南(四):子宫内膜癌[J].国际妇产科学杂志, 2008, 35(4):303-304.
[8] 周琦, 吴小华, 刘继红,等. 子宫内膜癌诊断与治疗指南(第四版)[J].中国实用妇科与产科杂志, 2018, 34(8):52-58.
[9] 张文靖, 杨建萍, 李晟磊. 组蛋白去乙酰化酶6在胃癌组织中的表达及意义[J].广东医学, 2012, 33(2):223-226.
[10] 韩文鹤,王晓彤,陈艳丽.乳腺癌术后接受内分泌治疗的患者发生子宫内膜癌的危险因素分析[J].医学临床研究,2021,38(3):428-430.
[11] 王少博, 戴礼猛, 章波. 组蛋白去乙酰化酶抑制剂TSA对食管癌细胞ncRNA/mRNA表达谱的影响[J].现代肿瘤医学, 2020, 28(11):6-9.
[12] 刘轩,乔晓娟,杜华,等. 组蛋白去乙酰化酶6在大肠癌中表达及意义[J].中华实用诊断与治疗杂志,2016,30(11):1089-1091.
[13] 张蕾, 刘好, 金平,等. 组蛋白去乙酰化酶抑制剂SAHA与紫杉醇联用诱导宫颈癌HeLa细胞凋亡的实验[J].肿瘤防治研究, 2018, 45(6):21-25.
[14] 王超,孙燕. 迁移侵袭抑制蛋白在肿瘤发生发展中的作用及其临床意义[J].中国肿瘤临床,2018,45(3):146-151.
[15] 张文斌, 王瑶, 焦方舟,等. 组蛋白去乙酰化酶6在相关疾病中的研究进展[J].疑难病杂志, 2019, 18(10):97-101.